Symbols

TNGX

Tango Therapeutics·NASDAQ

--(--)

Signals Analysis

Bullish signal 4

Bearish signal 1

Consensus Rating "Buy"

Ample Liquidity

High Gross Profit Margin

EPS Beats Expectation

Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About TNGX

Tango Therapeutics Inc.

A precision oncology company that develops therapeutic novel medicines targeting cancer vulnerbilities

Industry

Biological Technology

Established Date

05/21/2020

Listing Date

09/03/2020

Exchange

NASDAQ Stock Exchange

Full-time Employees

137

Fiscal Year Ends

12-31

Website

www.tangotx.com

Security Type

Common stock

Office address

201 Brookline Ave., Suite 901, Boston, MA 02215

Business

Introduction

Tango Therapeutics Inc., incorporated in Delaware on May 21, 2020, is a biotechnology company dedicated to discovering new drug targets and delivering next-generation precision medicine for the treatment of cancer. Tango uses a patient-starting and endpoint approach to discover and develop therapies for key cancer targets using the genetic principle of synthetic lethality. This includes expanding the scope of precise oncology targets into new areas, such as tumor suppressor gene loss and its contribution to the ability of cancer cells to evade immune cell killing.

Company Financials

EPS

TNGX has released its 2025 Q4 earnings. EPS was reported at -0.29, versus the expected -0.32, beating expectations. The chart below visualizes how TNGX has performed over recent quarters, highlighting trends in earnings surprises.